Serious heart-related side effects such as myocardial infarctions, strokes, and cardiovascular deaths associated with Imbruvica (ibrutinib), according to this medical journal article, “Hypertension and Incident Cardiovascular Events Following Ibrutinib Initiation”, published in early October 2019.
From the Abstract for this Blood medical journal article about Imbruvica we get these details:
We also evaluated the relationship of hypertension on [Imbruvica (ibrutinib)] to the development of other major-adverse-cardiovascular-events (MACE), including arrhythmias, myocardial infarction, stroke, heart failure, and cardiovascular death…. In multivariable regression containing known predictors of MACE, new or worsened hypertension was associated with increased MACE [hazard ratio (HR) 2.17, 95%CI 1.08-4.38].
In summary, these medical study findings suggest that: (1) Imbruvica is associated with a substantial increase in the incidence as well as the severity of hypertension; and, (2) Imbruvica-related hypertension development may lead to a greater than 2-time increased risk of subsequent cardiotoxic events.
As such, doctors and patients involved with Imbruvica should be aware of serious side effects including myocardial infarctions, strokes, and cardiovascular deaths associated with Imbruvica.[View article at original source]